These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 29530567)

  • 1. Induction therapy for locally advanced distal esophageal adenocarcinoma: Is radiation Always necessary?
    Liou DZ; Backhus LM; Lui NS; Shrager JB; Berry MF
    J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2697-2707. PubMed ID: 29530567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemoradiation therapy prior to esophagectomy is associated with superior long-term survival for esophageal cancer.
    Speicher PJ; Wang X; Englum BR; Ganapathi AM; Yerokun B; Hartwig MG; D'Amico TA; Berry MF
    Dis Esophagus; 2015; 28(8):788-96. PubMed ID: 25212528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
    Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
    J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in survival after trimodality therapy for esophageal adenocarcinoma.
    Eng OS; Nelson RA; Konstantinidis I; Chao J; Erhunmwunsee L; Raz DJ; Kim JY
    Dis Esophagus; 2018 Sep; 31(9):. PubMed ID: 29534155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
    Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
    JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Disparities After Induction Chemoradiotherapy and Esophagogastrectomy for Esophageal Cancer.
    Rowse PG; Jaroszewski DE; Thomas M; Harold K; Harmsen WS; Shen KR
    Ann Thorac Surg; 2017 Oct; 104(4):1147-1152. PubMed ID: 28842111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
    Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
    Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis.
    Raman V; Jawitz OK; Voigt SL; Yang CJ; D'Amico TA; Harpole DH
    J Surg Res; 2020 May; 249():82-90. PubMed ID: 31926400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stage III esophageal adenocarcinoma: definitive chemoradiation vs. chemoradiation plus surgery.
    Schlottmann F; Strassle PD; Gaber C; Patti MG
    Updates Surg; 2018 Dec; 70(4):423-426. PubMed ID: 29926306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer.
    Javidfar J; Speicher PJ; Hartwig MG; D'Amico TA; Berry MF
    Ann Thorac Surg; 2016 Mar; 101(3):1060-7. PubMed ID: 26576752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation field size and dose determine oncologic outcome in esophageal cancer.
    Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
    World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.